Anand B Karnad MD

Oncology•San Antonio, TX

Hematologic Oncology

Physician

Join to View Full Profile

7979 Wurzbach RdSan Antonio, TX 78229
Phone+1 210-450-1000
Fax+1 210-450-1150

Education & Training

Boston University Medical CenterFellowship, Hematology and Medical Oncology, 1985 - 1989
East Tennessee State University/Quillen College of MedicineResidency, Internal Medicine, 1982 - 1984
Madras Medical CollegeClass of 1981

Certifications & Licensure

TX State Medical License 2004 - 2025
TN State Medical License 1984 - 2004
GA State Medical License 1983 - 1989
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2006 Sep 26
ACTIVE_NOT_RECRUITING
PHASE3
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) Start of enrollment: 2006 Apr 07
ACTIVE_NOT_RECRUITING
PHASE3
S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo Start of enrollment: 2006 Oct 01
Completed
Phase 3
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases Start of enrollment: 2008 Dec 01
Completed
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
ACTIVE_NOT_RECRUITING
PHASE3
S0820, Adenoma and Second Primary Prevention Trial Start of enrollment: 2013 Aug 23
ACTIVE_NOT_RECRUITING
PHASE3
Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma Start of enrollment: 2013 Apr 01
Completed
Phase 1, Phase 2
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer Start of enrollment: 2012 Aug 01
Completed
Phase 2
Frailty Study of Older Adults Getting Chemotherapy and Radiation Therapy Start of enrollment: 2012 Feb 01
Terminated
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer Start of enrollment: 2013 Oct 22
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Start of enrollment: 2014 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Mar 10
ACTIVE_NOT_RECRUITING
PHASE3
Join now to see all

Publications & Presentations

PubMed

Pilot phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors.
Ranjit Banwait, Heidi Ko, Joel Michalek, Qianqian Liu, Kate Lathrop
International Journal of Cancer. 2025-04-15
1 citations
First-Line Combination of R-CHOP with the PDE4 Inhibitor Roflumilast for High-Risk DLBCL.
Adolfo E Diaz Duque, Pedro S S M Ferrari, Purushoth Ethiraj, Carine Jaafar, Zhijun Qiu
Cancers. 2024-11-18
Classical Hematology Referrals at an National Cancer Institute-Designated Cancer Center: Lessons Learned.
Chase V West, Matthew J Butler, Supreet Kaur, Elizabeth Bowhay-Carnes, Anand B Karnad
JCO Oncology Practice. 2024-01-01

Abstracts/Posters

Combination of Phosphodiesterase 4 (PDE4) Inhibitor Roflumilast and R-CHOP As First-Line Therapy for High-Risk Diffuse Large B Cell Lymphoma Patients
Anand Karnad, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Press Mentions

Mesa Departing March 2023December 12th, 2022
FDA Approves Immunotherapy Drug as First-Line Cancer TreatmentNovember 11th, 2016
Battling Cancer with ImmunotherapyNovember 11th, 2016

Grant Support

Protocol Review And Monitoring SystemNational Cancer Institute2009–2011
Clinical Trial: A PH II Study Of CNTO 328 Antibody Against IL-6 In PTS With PROSNational Center For Research Resources2008